Cart
sales@molnova.com
Home - Products - GPCR/G Protein - Antibacterial - Dalbavancin

Dalbavancin

CAS No. 171500-79-1

Dalbavancin( MDL-63397 | BI-397 )

Catalog No. M12613 CAS No. 171500-79-1

Dalbavancin(MDL-63397, BI-397) is a novel second-generation lipoglycopeptide antibiotic that exerts its bactericidal effect by disrupting cell wall biosynthesis.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 195 In Stock
5MG 123 In Stock
10MG 185 In Stock
25MG 373 In Stock
50MG 550 In Stock
100MG 784 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    Dalbavancin
  • Note
    Research use only, not for human use.
  • Brief Description
    Dalbavancin(MDL-63397, BI-397) is a novel second-generation lipoglycopeptide antibiotic that exerts its bactericidal effect by disrupting cell wall biosynthesis.
  • Description
    Dalbavancin(MDL-63397, BI-397) is a novel second-generation lipoglycopeptide antibiotic that exerts its bactericidal effect by disrupting cell wall biosynthesis.
  • In Vitro
    Dalbavancin is a parenterally administered semisynthetic lipoglycopeptide developed to combat infections caused by resistant gram-positive pathogens. Dalbavancin exhibits potent in vitro bactericidal activity against gram-positive pathogens including S. aureus (MRSA), VISA, and non-VanA strains of VRE. Dalbavancin is developed for the treatment of complicated skin and skin structure infections (cSSSIs), predominantly those caused by MRSA and β-hemolytic streptococci, organisms against which it has shown greater potency than existing glycopeptide therapeutic agents.
  • In Vivo
    Dalbavancin (15-240 mg/kg; intraperitoneal injection; every 36 h or 72 h; for 14 days; female BALB/c mice) treatment has a survival rate of 80% to 100% of mice with all dose regimens. Animal Model:Female BALB/c mice (6-8 weeks) challenged with Ames strain of B. anthracis Dosage:15 mg/kg, 30 mg/kg, 60 mg/kg, 120 mg/kg, 240 mg/kg Administration:Intraperitoneal injection; every 36 h or 72 h; for 14 days Result:The efficacy was 80 to 100%, as determined by the rate of survival at 42 days, when treatment was initiated 24 h postchallenge with regimens of 15 to 120 mg/kg every 36 h or 30 to 240 mg/kg every 72 h.
  • Synonyms
    MDL-63397 | BI-397
  • Pathway
    GPCR/G Protein
  • Target
    Antibacterial
  • Recptor
    Antibacterial
  • Research Area
    Infection
  • Indication
    ——

Chemical Information

  • CAS Number
    171500-79-1
  • Formula Weight
    1816.692
  • Molecular Formula
    C88H100Cl2N10O28
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: ≥ 24 mg/mL
  • SMILES
    CC(C)CCCCCCCCC(=O)NC1C(C(C(OC1OC2=C3C=C4C=C2OC5=C(C=C(C=C5)C(C6C(=O)NC(C7=C(C(=CC(=C7)O)OC8C(C(C(C(O8)CO)O)O)O)C9=C(C=CC(=C9)C(C(=O)N6)NC(=O)C4NC(=O)C1C2=C(C(=CC(=C2)OC2=C(C=CC(=C2)C(C(=O)NC(CC2=CC=C(O3)C=C2)C(=O)N1)NC)O)O)Cl)O)C(=O)NCCCN(C)C)O)Cl)C(=O)O)O)O
  • Chemical Name
    Ristomycin A aglycone, 5,31-dichloro-38-de(methoxycarbonyl)-7-demethyl-19-deoxy-56-O-[2-deoxy-2-[(10-methyl-1-oxoundecyl)amino]-β-D-glucopyranuronosyl]-38-[[[3-(dimethylamino)propyl]amino]carbonyl]-42-O-α-D-mannopyranosyl-N15-methyl-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Chen AY, et al. Int J Clin Pract. 2007 May;61(5):853-63. 2. Boucher HW, et al. N Engl J Med. 2014 Jun 5;370(23):2169-79.
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • Tigemonam

    Tigemonam is a monobactam, a novel orally administered monobactam that protects against gram-negative aerobic bacterial pathogens and is at least as active against clinical isolates of Enterobacteriaceae as amitraz or carmonan (MIC90: 0.06-16 mg/l).

  • PBP 10

    Selective formyl peptide receptor 2 (FPR2) antagonist; cell permeable. Selectively inhibits FPR2-mediated NADPH oxidase activity but has no effect on FPR1 signaling in neutrophils. Displays PIP2 binding activity in vitro and blocks cell motility. Also exhibits antiviral activity against influenza viruses via inhibition of viral-induced ERK activation.

  • Lanopepden mesylate

    Lanopepden mesylate is a peptide deformylase inhibitor against Staphylococcus aureus.

Sign In Join Free